Propanc Biopharma Inc. (PPCB): Forecast Levels Chart

Corporate company logo of Propanc Biopharma Inc (PPCB)

The price visualization on GURU.Markets, which assists in the basic asset valuation, shows the price action of Propanc Biopharma Inc (PPCB), whose operations are based on creating enzymatic tumor treatments with patent licensing potential. Propanc Biopharma Inc (PPCB) adheres to environmental standards and bioethics by reducing harmful emissions. Meanwhile, the investment profile is 380.60, remaining highly dependent on the clinical trial outcomes of its sole technological platform.

PPCB Propanc Biopharma: Analyst Consensus Forecast in the range 08/16/2025 - 11/11/2026

Metric breakdowns and analytics for Propanc Biopharma Inc (PPCB)

- share price and expert price forecast:
Quote Chart propanc.com|PPCB - Price Target Chart
- stock exchange capitalization data:
Market Valuation Propanc Biopharma Inc|PPCB - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value per Share Propanc Biopharma|PPCB - Book Capitalization|Market Value to Book Value Ratio propanc.com|PPCB - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Capital Propanc Biopharma Inc|PPCB - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio propanc.com|PPCB - Company Aggregate Debts|Debt to Book Value Propanc Biopharma Inc|PPCB - Company Long-Term Debt|Short-Term Debt Propanc Biopharma|Quick Liquidity propanc.com
- business earnings and investment ratios data:
PPCB - Company Net Income|Expected Net Profit Propanc Biopharma Inc|PPCB - P/E Multiple|Forward Price to Earnings Multiple propanc.com|PPCB - Price/Earnings to Growth Multiple|Company Value to EBITDA Propanc Biopharma Inc|PPCB - Operating profit before deduction of amortization|Earnings per share for the trailing year Propanc Biopharma|PPCB - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months propanc.com|PPCB - Earnings growth in current year|Earnings growth forecast for next year Propanc Biopharma Inc
General company analysis:PPCB (Propanc Biopharma Inc.)
Mass-produced product of Propanc Biopharma Inc.

Propanc Biopharma Inc (PPCB) develops innovative enzyme drugs to eliminate cancer stem cells, aiming to prevent tumor recurrence. The current market consensus target reflects the average business acquisition value, allowing investors to determine a fair discount to the share price and assess the asset's attractiveness to a strategic buyer, while avoiding an overestimation of the therapy's prospects amid market expectations.

Competitors of Propanc Biopharma Inc

GMAB: Forecast Levels Chart|Price Target Chart Exelixis EXEL|NUVL (Nuvalent Inc) - Forecast Levels Chart|Kymera Therapeutics Inc - Analyst Consensus Forecast|IDEAYA Corp (IDYA) - Consensus Target|ELVN: Analyst Consensus Forecast|ORIC (oricpharma.com) - Price Target Chart|Price Target Chart Relay Therapeutics, Inc.|Average Forecast Price Nurix Therapeutics Inc NRIX|Price Target Chart Tyra Bio (TYRA)|Verastem Corp - Broker Consensus Forecast|Analyst Consensus Forecast GLUE (Monte Rosa Therapeutics)|CGEM - Consensus Target|IMRX - Price Target Chart|Average Forecast Price C4 Therapeutics Inc|Black Diamond Therapeutics Inc. (BDTX) - Price Target Chart|RPTX (Repare Therapeutics Inc) - Price Target Chart|Price Target Chart PMV Pharmaceuticals|Average Forecast Price Karyopharm KPTI|Analyst Consensus Forecast BGMS|aadibio.com (AADI) - Analyst Target Range|Aileron Therapeutics, Inc. - Consensus Target|Blueprint Medicines Corp. (BPMC) - Average Forecast Price|GLYC: Consensus Target|Fair Value Consensus SWTX (springworkstx.com)